Kappa/Lambda Light Chain Panel by in situ Hybridization on Paraffin

Also known as: K/L P ISH

Clinical Use

Use

The Kappa/Lambda Light Chain Panel by in situ Hybridization is used to quantify kappa and lambda light chains in paraffin-embedded tissues. It aids in the diagnosis and classification of B-cell lymphoproliferative disorders and plasma cell neoplasms by assessing the clonality of light chain expression. The presence of a monoclonal population may indicate a neoplastic process, whereas a polyclonal population is typically associated with reactive conditions.

Special Instructions

Not provided.

Limitations

This test was developed and its performance characteristics were determined by ARUP Laboratories and has not been cleared or approved by the FDA. It should be performed in a CLIA certified laboratory. The test is not intended to detect all possible genetic mutations in the immunoglobulin molecules and may not detect low levels of kappa or lambda mRNA. Proper specimen handling is critical to ensure accuracy of test results.

Test Details

New York Approved

Methodology

Chromosomal / Cytogenetics (ISH)

Biomarkers

2 components

Kappa/Lambda ISH Clonality • ISHKappa/Lambda ISH Ratio • ISH

Result Turnaround Time

2-5 days

Specimen

Tissue (FFPE)

Volume

Not provided

Minimum Volume

5 slides

Container

tissue transport kit (ARUP supply #47808)

Collection Instructions

Collect tissue and fix in 10 percent neutral buffered formalin. Paraffin-embed tissue block or prepare 10 unstained 5 micron slides. Transport in a tissue transport kit, obtainable through eSupply using ARUP Connect or by contacting ARUP Client Services.

Storage Instructions

Protect paraffin block and/or slides from excessive heat. Ship in cooled container during summer months.

Causes for Rejection

Paraffin block with no tumor tissue remaining. Specimens fixed in any fixative other than 10 percent neutral buffered formalin. Decalcified specimens.